NutriPATH Pty Ltd

NutriPATH Pty Ltd, based in Australia, specializes in functional pathology testing services. The company supports healthcare providers with over 200 tests to assist in diagnosing health issues and improving patient outcomes. NutriPATH Pty Ltd operates as a specialty clinical laboratory providing a comprehensive range of functional pathology testing services. Founded in 2011, the company is headquartered in Australia and has engaged in a total of 1 deal.

The most recent deal occurred on March 2, 2026, when it was acquired by US BioTek Laboratories, LLC, a portfolio company of Pike Street Capital. Financial terms of the acquisition were not disclosed. NutriPATH is a specialty clinical laboratory that provides an extensive range of functional pathology testing services, with over 200 pathology tests available, making it one of the largest integrative medical laboratories in its sector. The company employs a systems approach that supports healthcare providers in diagnosing the underlying causes of illness and promoting health and wellbeing.

NutriPATH's offerings include specialized functional tests that cover various health categories such as allergies, hormone health, mental health, microbiome health, nutritional analysis, and oncology. Their client base primarily consists of professional healthcare providers, including general practitioners and wellness practitioners, who utilize NutriPATH’s services to aid in patient care and disease prevention. The company serves a diverse geographical market, providing services not only within Australia but also on a global scale, thereby catering to a broad audience of healthcare professionals and their patients. NutriPATH's revenue model is primarily structured around B2B transactions with healthcare practitioners who order tests on behalf of their patients through an online portal.

Each test ordered is accompanied by a test kit sent directly to the patient, who then collects their sample at home and returns it for analysis using pre-provided courier packaging. This streamlined process allows for convenient testing and analysis, bolstering client satisfaction and retention. While specific pricing details are not disclosed, the company offers a comprehensive suite of specialized tests, with flagship offerings such as Nutritional Analysis and various hormone health assessments. This structure not only generates revenue from individual test orders but also positions NutriPATH as a trusted partner for healthcare providers seeking to deliver advanced diagnostic capabilities.

In March 2026, the acquisition by US BioTek Laboratories, LLC aims to enhance business development strategies, indicating potential for expanding NutriPATH's product offerings and market reach. The future growth strategy may involve the design and launch of new specialized tests, along with targeting expansion into new geographic regions. Specific plans for market penetration or the introduction of new services have yet to be detailed, but the acquisition aligns with enhancing NutriPATH's capabilities in the functional pathology sector.